School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Comput Math Methods Med. 2022 Nov 26;2022:2615580. doi: 10.1155/2022/2615580. eCollection 2022.
Chronic obstructive pulmonary disease (COPD) is becoming a major public health burden worldwide. It is urgent to explore more effective and safer treatment strategy for COPD. Notably, Xuefu Zhuyu Decoction (XFZYD) is widely used to treat respiratory system diseases, including COPD, in China.
This study is aimed at comprehensively evaluating the therapeutic effects and molecular mechanism of XFZYD on COPD.
Original clinical studies were searched from eight literature databases. Meta-analysis was conducted using the Review Manager software (version 5.4.1). Network pharmacology and molecular docking experiments were utilized to explore the mechanisms of action of XFZYD.
XFZYD significantly enhanced the efficacy of clinical treatment and improved the pulmonary function and hypoventilation of COPD patients. In addition, XFZYD significantly improved the hypercoagulability of COPD patients. The subgroup analysis suggested that XFZYD exhibited therapeutic effects on both stable and acute exacerbation of COPD. XFZYD exerted its therapeutic effects on COPD through multicomponent, multitarget, and multipathway characteristics. The intervention of the PI3K-AKT pathway may be the critical mechanism.
The application of XFZYD based on symptomatic relief and supportive treatment is a promising clinical decision. More preclinical and clinical studies are still needed to evaluate the safety and therapeutic effects of long-term use of XFZYD on COPD.
慢性阻塞性肺疾病(COPD)在全球范围内正成为一个主要的公共卫生负担。探索更有效和更安全的 COPD 治疗策略迫在眉睫。值得注意的是,血府逐瘀汤(XFZYD)在中国被广泛用于治疗呼吸系统疾病,包括 COPD。
本研究旨在全面评估 XFZYD 治疗 COPD 的疗效和分子机制。
从八个文献数据库中检索原始临床研究。使用 Review Manager 软件(版本 5.4.1)进行荟萃分析。利用网络药理学和分子对接实验来探讨 XFZYD 的作用机制。
XFZYD 显著提高了临床治疗的疗效,改善了 COPD 患者的肺功能和通气不足。此外,XFZYD 还显著改善了 COPD 患者的高凝状态。亚组分析表明,XFZYD 对 COPD 的稳定期和急性加重期均有治疗作用。XFZYD 通过多成分、多靶点、多途径的特点发挥对 COPD 的治疗作用。干预 PI3K-AKT 通路可能是其关键机制。
基于症状缓解和支持性治疗的 XFZYD 的应用是一种有前途的临床决策。仍需要更多的临床前和临床试验来评估 XFZYD 长期用于 COPD 的安全性和治疗效果。